Clinical Trials

Cyclacel Pharmaceuticals is currently evaluating the following oncology drug candidates in clinical trials:

Sapacitabine (CYC682): sapacitabine is an orally-available nucleoside analogueue with a novel mechanism; interfering with DNA synthesis by introducing single-strand DNA breaks leading to arrest of cell cycle progression in G2-Phase and development of double-strand DNA breaks.

Learn more about sapacitabine trial(s) on ClinicalTrials.gov
Seliciclib (CYC202): seliciclib is an orally-available cyclin-dependent kinases (CDKs) inhibitor. The compound selectively inhibits enzyme targets CDK2, CDK7 and CDK9 that are central to the process of cell division and cell cycle control.

Learn more about seliciclib trial(s) on ClinicalTrials.gov

These candidates are experimental drugs under clinical investigation. They are not approved for human use.